Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates.

Pharmaceutics · 2021 · PMC8233734 · PMID 34205780

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, Slco2b1 (-/-) mice showed a trend towards a decrease in the k 2 parameter ( Figure 7 ), which may be related to a reduced expression of hepatic MRP3 which was shown to mediate the efflux of [ 99m Tc]mebrofenin from the liver into the blood [ 21 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Imaging-Based Characterization of a &lt;i&gt;Slco2b1&lt;sup&gt;(-/-)&lt;/sup&gt;&lt;/i&gt; Mouse Model Using [&lt;sup&gt;11&lt;/sup&gt;C]Erlotinib and [&lt;sup&gt;99m&lt;/sup&gt;Tc]Mebrofenin as Probe Substrates.

The sentences

Imaging-Based Characterization of a <i>Slco2b1<sup>(-/-)</sup></i> Mouse Model Using [<sup>11</sup>C]Erlotinib and [<sup>99m</sup>Tc]Mebrofenin as Probe Substrates.